Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
about
Aptamers: A Feasible Technology in Cancer ImmunotherapyPD-1/PD-L1 blockade in cancer treatment: perspectives and issuesToxicity profile of approved anti-PD-1 monoclonal antibodies in solid tumors: a systematic review and meta-analysis of randomized clinical trialsAptamers: A New Technological Platform in Cancer ImmunotherapyFocus on Nivolumab in NSCLCAdvances in Cancer Immunotherapy in Solid TumorsCheckpoint inhibitors in hematological malignanciesJapanese Kampo medicine ninjin'yoeito synergistically enhances tumor vaccine effects mediated by CD8+ T cellsEmerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab.Inflammatory Arthritis: A Newly Recognized Adverse Event of Immune Checkpoint BlockadeBET Bromodomain Inhibition Promotes Anti-tumor Immunity by Suppressing PD-L1 Expression.PD-1, PD-L1 (B7-H1) and Tumor-Site Immune Modulation Therapy: The Historical Perspective.Combination immunotherapy: a road map.PD-1 blockade attenuates immunosuppressive myeloid cells due to inhibition of CD47/SIRPα axis in HPV negative head and neck squamous cell carcinoma.Enhanced Anti-tumor Reactivity of Cytotoxic T Lymphocytes Expressing PD-1 DecoyPembrolizumab-associated sarcoidosisGrover's-like drug eruption in a patient with metastatic melanoma under ipilimumab therapy.Incidence and risk of hepatic toxicities with PD-1 inhibitors in cancer patients: a meta-analysis.Chimeric antigen receptor T cells secreting anti-PD-L1 antibodies more effectively regress renal cell carcinoma in a humanized mouse modelRecurrent pleural effusions and cardiac tamponade as possible manifestations of pseudoprogression associated with nivolumab therapy- a report of two cases.Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor TherapyPD-1 inhibitors increase the incidence and risk of pneumonitis in cancer patients in a dose-independent manner: a meta-analysis.Combining a GSI and BCL-2 inhibitor to overcome melanoma's resistance to current treatments.Clinical value of monoclonal antibodies and tyrosine kinase inhibitors in the treatment of head and neck squamous cell carcinoma.Cancer immunotherapies targeting the PD-1 signaling pathway.Limitations and opportunities for immune checkpoint inhibitors in pediatric malignancies.Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy.Cost-Effectiveness of Nivolumab-Ipilimumab Combination Therapy Compared with Monotherapy for First-Line Treatment of Metastatic Melanoma in the United States.Immune Checkpoint Inhibitors in Gliomas.Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients.Anti-EGFR and antiangiogenic monoclonal antibodies in metastatic non-small-cell lung cancer.The emerging role of immune checkpoint inhibition in malignant lymphoma.Immune checkpoint inhibition in ovarian cancer.Local delivery of checkpoints antibodies.Immunotherapy for oesophagogastric cancer.Checkpoint inhibitors and other novel immunotherapies for advanced renal cell carcinoma.Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents.Nivolumab in the treatment of metastatic squamous non-small cell lung cancer: a review of the evidence.Safety and Tolerability of PD-1/PD-L1 Inhibitors Compared with Chemotherapy in Patients with Advanced Cancer: A Meta-Analysis.Monitoring and Management of Immune-Related Adverse Events Associated With Programmed Cell Death Protein-1 Axis Inhibitors in Lung Cancer.
P2860
Q26740303-4C806CE4-393D-4F45-85AB-5280F39D9FA3Q26768641-A4710ABA-2871-471D-8C41-8E64F70EFF2EQ28067583-5AB70108-6C38-4A59-A359-50F6AF1EBCA9Q28068981-9074130E-7095-47B7-9DC1-36403EBB6455Q28073759-FC897E16-8B2C-4835-A805-F07BDC0086F1Q28080113-C3C78E2E-B52E-49DA-B89D-924B953709B1Q33651495-23C3C5CC-2618-4120-BCA4-FBD5E6D08DBEQ33686036-1ECB2891-FFB5-49A3-887F-1BFAAC4D13B9Q33704061-A1E5F2B2-432D-4876-84F1-DFADD422B6FEQ33793552-12BB3686-3447-4AE5-A130-FC6259D12B24Q34047394-DA3C8010-CCF9-45F2-BC90-5AF9D4C6C4C4Q34550012-12DD2FD7-4561-414D-AB81-40CBF6B43E8EQ34552128-8E2F9D74-2903-49A1-9403-B310A3D68E09Q36561681-D5E47511-3A9D-4604-9251-1504D8AB0AD4Q36859353-F17BE218-8313-42B2-87CA-B2A0C1B91A8DQ37143608-19BD5EAD-5B1F-4F6C-B5B6-E05FCB7CC358Q37178600-F4F2F67D-47A9-4854-9D6E-D3A4BFED89FDQ37306007-6DE095A3-A67B-472D-A1FC-AEFD35C9C1FDQ37376269-D415BD22-0D9F-47D9-B8AC-B1E5304652B2Q37414589-4F15DD17-EB2E-4A97-9E78-4E435CDCA303Q37629874-D3E4A9B6-2D88-4FE3-939E-A2604EB2A9ABQ37685959-9FDB5964-5316-46A9-8E00-377CE926DA28Q37708989-B86FE13F-ED91-4492-86CF-86874D2FD619Q37709902-38861682-3387-46B9-B503-D86891ED5991Q37737940-96240024-CA11-4CC9-A54B-8CAD2085FD51Q38670099-B53376F1-12C9-428B-A8BC-14FDC8281AF7Q38672084-B4783940-8584-40C1-84F0-0B81A44E1E26Q38680945-2CD11D3A-48B8-4D51-A4DB-911F04664769Q38743793-3DFDA018-5E4F-43EB-98B5-1C5D456610AFQ38752269-008111BA-AE64-4B17-8886-92E01CE78F1FQ38763641-D309876E-C226-49A5-9677-04449ACD9264Q38791036-3C808BDD-73B8-4CC3-8C87-C78E88B6D4F8Q38800974-926C2D4E-DFE3-4336-953E-FE8830C1998FQ38817657-D817B79E-BCEB-416A-8583-E716306A579DQ38842511-4D9FB405-A2D5-4DE1-B4E6-B8F6B8958A15Q38870929-D143D9AF-996F-4C7D-8F88-084A6F18D367Q38893086-C62E753C-8D71-4664-A116-FC32F5D9368AQ38915130-D48FB74A-745A-4921-B6CB-484B44920B8EQ38919707-495E8B64-87CC-4DCC-BDA7-13C249DE66D9Q38930084-77E76C0A-1ED6-4F61-8789-5D5E6EF52A9B
P2860
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
@en
type
label
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
@en
prefLabel
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies.
@en
P2093
P2860
P356
P1433
P1476
Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies
@en
P2093
J D Wolchok
K Schindler
L C Connell
M A Postow
P2860
P304
P356
10.1093/ANNONC/MDV383
P577
2015-09-14T00:00:00Z